Study of strategy for secondary failure of infliximab maintenance therapy to measure anti-infliximab antibody levels in patients with inflammatory bowel disease.

Trial Profile

Study of strategy for secondary failure of infliximab maintenance therapy to measure anti-infliximab antibody levels in patients with inflammatory bowel disease.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2017

At a glance

  • Drugs Infliximab (Primary) ; Adalimumab
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms IFXATIIBD
  • Most Recent Events

    • 21 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top